HealthCap

DOYLESTOWN, Pa , Jan 11, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc (Nasdaq: APRE), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, today announced that the first pat

read more

• January 11, 2023 Oncopeptides appoints Holger Lembre
• STOCKHOLM — January 11, 2023 — Oncopeptides AB (publ
• ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today announces that the Company has appointed Holger Lembrer as Chief Financial Officer, CFO
• Prior
• read more STOCKHOLM — January 11, 2023 — Oncopeptides AB (publ ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today announces that the Company has appointed Holger Lembrer as Chief Financial Officer, CFO Prior

read more

• January 10, 2023 Hemab Therapeutics Announces First
• Bispecific antibody HMB-001 positioned as the first prophylactic treatment for rare bleeding disorders CEO Benny Sorensen, MD, PhD, delivered the update during a corporate overview presented at the 41st Annual JP Morgan Healthcare Conference COPENHAGEN, DENMARK AND BOSTON, MASS
• , US
• read more Bispecific antibody HMB-001 positioned as the first prophylactic treatment for rare bleeding disorders CEO Benny Sorensen, MD, PhD, delivered the update during a corporate overview presented at the 41st Annual JP Morgan Healthcare Conference COPENHAGEN, DENMARK AND BOSTON, MASS , US

read more

• January 9, 2023 Spruce Biosciences Provides Clinica
• Topline Results from CAHmelia-203 in Adult Classic Congenital Adrenal Hyperplasia (CAH) Anticipated in 2H 2023 Amendment to Phase 2 CAHptain Clinical Trial in Pediatric Classic CAH Enhances Study Design; Topline Data from Adolescents Anticipated in 2H 2023 Topline Data in Phase 2 P
• O
• W
• E
• R
• S
• read more Topline Results from CAHmelia-203 in Adult Classic Congenital Adrenal Hyperplasia (CAH) Anticipated in 2H 2023 Amendment to Phase 2 CAHptain Clinical Trial in Pediatric Classic CAH Enhances Study Design; Topline Data from Adolescents Anticipated in 2H 2023 Topline Data in Phase 2 P O W E R S

read more

• December 23, 2022 Q3 2022 General Market Overview
• October 07, 2021 HealthCap strengthens senior team
• November 29, 2021 HealthCap’s 25th company anniversary! HealthCap is a European venture capital firm investing exclusively and globally in life sciences The investment strategy focuses on diseases with high unmet medical needs and breakthrough therapies that have the potential to be transformative

I consent to the collection of my personal data according to the current privacy policy